Compare Incyte Corporation (INCY) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs LTC Properties Inc — how do they compare? Incyte Corporation trades at $112.64 (market cap $22.85B), while LTC Properties Inc trades at $42.35 (market cap $2.27B). The key difference: Incyte Corporation is far larger — about 10.1× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and LTC Properties Inc for 89 Days on average.
| INCY | LTC | |
|---|---|---|
Market Cap | $22.85B | $2.27B |
Volume | 1,927,029 | 574,171 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $43.50 |
52-Week Low | $83.80 | $33.98 |
Typical Hold Time | 33 Days | 89 Days |
Enterprise Value | $18.35B | $3.01B |
Dividend Yield | — | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
LTC Properties trades at $42.37, up 1.34% with a bullish technical signal. The REIT shows strong fundamentals with 2025 revenue of $262.85M and net income of $117.97M, delivering a 38.93% net margin. Recent acquisitions totaling $360M accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Analyst consensus sits at $49.67 with mixed ratings (7 Buy, 12 Hold, 3 Sell) amid strategic shifts.
Outlook remains positive due to demographic tailwinds in senior housing, though rising rates and execution risks on $730M asset sales pose challenges. Current valuation at P/E 15.02 appears reasonable for growth prospects, with technical support at $41-42 offering near-term stability. The stock presents a balanced opportunity for income and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
